Home
Resources
Publications
Novel anti-EPHA2 Antibody, DS-8895a for Cancer Treatment

Novel anti-EPHA2 Antibody, DS-8895a for Cancer Treatment

Jun Hasegawa, Mayumi Sue, Michiko Yamato, Junya Ichikawa, Saori Ishida, Tomoko Shibutani, Michiko Kitamura, Teiji Wada, Toshinori Agatsuma

Cancer Biol Ther. 2016 Nov;17(11):1158-1167.

PMID: 27653549

Abstract:

Overexpression of EPHA2 has been observed in multiple cancers and reported to be associated with poor prognosis. Here, we produced an afucosylated humanized anti-EPHA2 monoclonal antibody (mAb), DS-8895a for cancer treatment. The antibody recognizes the extracellular juxtamembrane region of EPHA2 and therefore can bind to both full-length and truncated forms of EPHA2, which are anchored to cell membranes and recently reported to be produced by post-translational cleavage in tumors. DS-8895a exhibited markedly increased antibody dependent cellular cytotoxicity (ADCC) in vitro and also inhibited tumor growth in EPHA2-positive human breast cancer MDA-MB-231 and human gastric cancer SNU-16 xenograft mouse models. Moreover, DS-8895a in combination with cisplatin (CDDP) showed better efficacy than each of the monotherapies did in the human gastric cancer model. These results suggest that a novel antibody, DS-8895a has therapeutic potential against EPHA2-expressing tumors.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
IAR42413556	Monoclonal Anti-EPHA2 antibody produced in mouse			Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: